Sherer Benjamin A, Godlewski Karl F, Levine Laurence A
Rush University Medical Center , 1725 W Harrison St, Chicago, IL 60612, Suite 348 , USA +1 312 563 3480 ; +1 312 563 5007 ;
Expert Opin Pharmacother. 2015 Jun;16(9):1299-311. doi: 10.1517/14656566.2015.1041503. Epub 2015 Apr 30.
Peyronie's disease (PD) is a wound healing disorder of the penis with a myriad of proposed treatment options reported in the literature. Evaluating the available data and therapeutic management of PD can be challenging and confusing, even for the most experienced treating physician. This review provides a comprehensive overview of pharmacologic treatment options for PD, focusing on the best available evidence.
A comprehensive literature search for published articles evaluating oral, topical, and injectable pharmacologic agents for PD was completed. Prospective, controlled trials were given precedence for inclusion.
Although a multitude of oral agents have been proposed and evaluated in PD patients, results vary widely and a reproducible objective benefit has not yet been strongly established for any single oral agent. Well-designed, large-scale, randomized controlled trials evaluating oral agents in PD patients are lacking. Consistent objective benefit from injectable agents has been supported for years by various non-controlled trials. Recently, injectable collagenase Clostridium histolyticum became the first pharmacologic agent to obtain FDA approval for use in PD patients, supported by data from a large-scale, Phase III randomized controlled trial. Further elucidation of the genetic and mechanistic pathways involved in the development and progression of PD will help define future therapeutic targets.
佩罗尼氏病（PD）是一种阴茎伤口愈合障碍疾病，文献中报道了众多的治疗方案。即使对于经验最丰富的治疗医生来说，评估PD的现有数据和治疗管理也可能具有挑战性且令人困惑。本综述全面概述了PD的药物治疗方案，重点关注现有最佳证据。
完成了一项全面的文献检索，以查找评估用于PD的口服、局部和注射用药物的已发表文章。优先纳入前瞻性对照试验。
尽管已在PD患者中提出并评估了多种口服药物，但结果差异很大，尚未明确确立任何单一口服药物具有可重复的客观益处。缺乏设计良好、大规模、评估PD患者口服药物的随机对照试验。多年来，各种非对照试验支持注射用药物具有一致的客观益处。最近，注射用溶组织梭菌胶原酶成为首个获得美国食品药品监督管理局（FDA）批准用于PD患者的药物，这得到了一项大规模III期随机对照试验数据的支持。进一步阐明参与PD发生和发展的遗传和机制途径将有助于确定未来的治疗靶点。
